Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Charles River Laboratories International's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 5.11%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
CRL's 10-Year ROIIC % is ranked better than 58.43% of 178
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.47
vs CRL: 5.11
Charles River Laboratories International (NYSE:CRL) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Charles River Laboratories International 10-Year ROIIC % Related Terms
Charles River Laboratories International 10-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International 10-Year ROIIC % Chart
Charles River Laboratories International Annual Data
CRL vs RVTY, QGEN, ICLR: 10-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International 10-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's 10-Year ROIIC % falls into.
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( 401.136 (Dec. 2025) - 160.617322 (Dec. 2015) )
/
( 6502.767 (Dec. 2025) - 1791.697 (Dec. 2015) )
=
240.518678
/
4711.07
=
5.11%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Charles River Laboratories International (CRL) has a 10-Year ROIIC % of 5.11 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Charles River Laboratories International and its competitors. According to the industry distribution chart, Charles River Laboratories International ranks #74 out of 178 companies in the Medical Diagnostics & Research industry, placing it in the top 41.6%.
Is Charles River Laboratories International's 10-Year ROIIC % too high?
Charles River Laboratories International's current 10-Year ROIIC % is 5.11. The Medical Diagnostics & Research industry median 10-Year ROIIC % is 1.47. Charles River Laboratories International's value of 5.11 is 247.6% above this industry median. Based on the distribution chart, Charles River Laboratories International ranks #74 out of 178 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's 10-Year ROIIC % compare to RVTY and QGEN?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #74 out of 178 companies for 10-Year ROIIC %. This puts Charles River Laboratories International in the upper half of its industry. The industry median 10-Year ROIIC % is 1.47. Charles River Laboratories International's value of 5.11 is 247.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Diagnostics & Research company?
The median 10-Year ROIIC % among Medical Diagnostics & Research companies is 1.47, based on 178 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current 10-Year ROIIC % of 5.11 is 247.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median 10-Year ROIIC % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current 10-Year ROIIC % is 5.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Modestly Overvalued. The stock's GF Value™ is $194.04, compared to a current price of $219.40 — trading 13.1% above its estimated fair value. The current 10-Year ROIIC % is 5.11 and 247.6% above the Medical Diagnostics & Research industry median of 1.47. Charles River Laboratories International's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current 10-Year ROIIC % is 5.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of $219.40 is trading 13.1% above its estimated GF Value™ of $194.04.
GuruFocus considers Charles River Laboratories International to be Modestly Overvalued.
Key valuation signals for CRL:
10-Year ROIIC %: 5.11
GF Value™: $194.04 vs. price of $219.40 (13.1% above fair value)
Industry Position: 247.6% above the Medical Diagnostics & Research median (#74 of 178)
No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories International Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
70GF Score
Get the complete analysis for CRL
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRL has been successfully added to your 
